P Grassi1, D Strianese2, R Piscopo3, R Pacelli4, G Bonavolontà2. 1. Department of Neuroscience, Odontostomatological and Reproductive Sciences, University "Federico II" of Naples, via Pansini no 5, 80131, Naples, Italy. pjgrassi@libero.it. 2. Department of Neuroscience, Odontostomatological and Reproductive Sciences, University "Federico II" of Naples, via Pansini no 5, 80131, Naples, Italy. 3. Department of Ophthalmology, Humanitas Research Hospital, Rozzano, Milan, Italy. 4. Department of Diagnostic Imaging and Radiotherapy, University "Federico II" of Naples, Naples, Italy.
Abstract
BACKGROUND AND AIMS: To evaluate the efficacy of orbital radiotherapy (OR) for the treatment of thyroid eye disease (TED). METHODS: Thirty-five consecutive patients with active TED with contraindications to steroid therapy received a course of OR. Bilateral retrobulbar irradiation was performed with a total dose of 20 Gy. 7-points clinical activity score (7-CAS), ocular motility, visual acuity (VA), exophthalmos and eyelid retraction were prospectively evaluated at 3, 6 and 12 months and compared with baseline data. RESULTS: There was a statistically significant improvement in 7-CAS at 3, 6 and 12 months post-treatment (p < 0.05). Ocular motility disturbances improved at 6 and 12 months (p < 0.05). Visual acuity remained stable; there was no significant change in exophthalmos (mean 24 mm, SD 3 mm) or eyelid retraction (marginal reflex distance mean 6 mm, SD 1.5 mm) during the follow-up period. No side effects were registered. CONCLUSIONS: This study suggests that OR might be effective in reducing 7-CAS and ocular motility disturbances. No significant improvement in proptosis or eyelid retraction should be expected from this treatment. OR might be considered a suitable alternative treatment in TED for patients who cannot tolerate steroids.
BACKGROUND AND AIMS: To evaluate the efficacy of orbital radiotherapy (OR) for the treatment of thyroid eye disease (TED). METHODS: Thirty-five consecutive patients with active TED with contraindications to steroid therapy received a course of OR. Bilateral retrobulbar irradiation was performed with a total dose of 20 Gy. 7-points clinical activity score (7-CAS), ocular motility, visual acuity (VA), exophthalmos and eyelid retraction were prospectively evaluated at 3, 6 and 12 months and compared with baseline data. RESULTS: There was a statistically significant improvement in 7-CAS at 3, 6 and 12 months post-treatment (p < 0.05). Ocular motility disturbances improved at 6 and 12 months (p < 0.05). Visual acuity remained stable; there was no significant change in exophthalmos (mean 24 mm, SD 3 mm) or eyelid retraction (marginal reflex distance mean 6 mm, SD 1.5 mm) during the follow-up period. No side effects were registered. CONCLUSIONS: This study suggests that OR might be effective in reducing 7-CAS and ocular motility disturbances. No significant improvement in proptosis or eyelid retraction should be expected from this treatment. OR might be considered a suitable alternative treatment in TED for patients who cannot tolerate steroids.
Entities:
Keywords:
Alternative first-line therapy; Graves ophthalmopathy; Orbital radiotherapy; Thyroid eye disease
Authors: Peter J Dolman; Kenneth Cahill; Craig N Czyz; Raymond S Douglas; Victor M Elner; Steven Feldon; Michael Kazim; Mark Lucarelli; Jennifer Sivak-Collcott; Andrew W Stacey; Diego Strianese; Jimmy Uddin Journal: Ophthalmology Date: 2011-09-29 Impact factor: 12.079
Authors: Y Nagayama; M Izumi; T Kiriyama; N Yokoyama; S Morita; F Kakezono; S Ohtakara; I Morimoto; S Okamoto; S Nagataki Journal: Acta Endocrinol (Copenh) Date: 1987-12
Authors: Luigi Bartalena; Claudio Marcocci; Maria Laura Tanda; Roberto Rocchi; Barbara Mazzi; Giuseppe Barbesino; Aldo Pinchera Journal: Thyroid Date: 2002-03 Impact factor: 6.568
Authors: C A Gorman; J A Garrity; V Fatourechi; R S Bahn; I A Petersen; S L Stafford; J D Earle; G S Forbes; R W Kline; E J Bergstralh; K P Offord; D M Rademacher; N M Stanley; G B Bartley Journal: Ophthalmology Date: 2001-09 Impact factor: 12.079
Authors: Luca Nicosia; Chiara Reverberi; Linda Agolli; Luca Marinelli; Vitaliana De Sanctis; Giuseppe Minniti; Maurizio Valeriani; Mattia F Osti Journal: Int J Endocrinol Metab Date: 2019-01-27